"The U.S. Food and Drug Administration today approved Hysingla ER (hydrocodone bitartrate), an extended-release (ER) opioid analgesic to treat pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternat"...
There is limited experience with overdose of Flector Patch (diclofenac epolamine topical patch) . In clinical studies, the maximum single dose administered was one Flector Patch containing 180 mg of diclofenac epolamine. There were no serious adverse events.
Should systemic side effects occur due to incorrect use or accidental overdose of this product, the general measures recommended for intoxication with non-steroidal anti-inflammatory drugs should be taken.
For additional information about overdose treatment, call a poison control center (1-800-222-1222).
- Flector Patch (diclofenac epolamine topical patch) is contraindicated in patients with a known hypersensitivity to diclofenac.
- Flector Patch (diclofenac epolamine topical patch) is contraindicated in patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients [see WARNINGS AND PRECAUTIONS].
- Flector Patch (diclofenac epolamine topical patch) is contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery [see WARNINGS AND PRECAUTIONS].
- Flector Patch (diclofenac epolamine topical patch) is contraindicated for use on non-intact or damaged skin resulting from any etiology, including exudative dermatitis, eczema, infection lesions, burns or wounds.
Last reviewed on RxList: 3/18/2011
Additional Flector Patch Information
Flector Patch - User Reviews
Flector Patch User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
Chronic Pain/Back Pain
Find tips and advances in treatment.